Ignyta Inc

163 articles about Ignyta Inc

• Ignyta Receives FDA Orphan Drug Designation For Entrectinib For Treatment Of NTRK Fusion-Positive Solid Tumors

  7/10/2017

• The FDA Calls Ignyta's Tumor Drug Entrectinib A Breakthrough

  5/15/2017

• Ignyta Granted Breakthrough Therapy Designation For Entrectinib By U.S. FDA

  5/15/2017

• Ignyta Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

  5/10/2017

• Ignyta Announces Pricing Of Public Offering Of Common Stock

  5/4/2017

• Ignyta Announces Proposed Public Offering Of Common Stock

  5/3/2017

• Ignyta Announces First Quarter 2017 Company Highlights And Financial Results

  5/2/2017

• Ignyta Updates Progress Towards Entrectinib Dual TRK And ROS1 NDA Submissions

  4/28/2017

• Ignyta To Host Conference Call And Webcast Update On Entrectinib Program And STARTRK-2 On April 27, 2017

  4/25/2017

• Ignyta Announces Peer-Reviewed Publication Of Activity Of A TRK Inhibitor In A Primary Brain Tumor: Successful Treatment Of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published In Precision Oncology

  3/30/2017

• Ignyta Announces Exploration Of Strategic Options For Taladegib, Enabled By Amendment Of Taladegib License Agreement With Eli Lilly

  3/24/2017

• Ignyta Announces Full Year 2016 Company Highlights And Financial Results

  3/15/2017

• Angsana's RNA-Based Fusions Cancer Panel Selected For Ignyta's STARTRK2 Clinical Trial In Asia-Pacific

  3/3/2017

• Ignyta's Updated Phase 1 Data On Safety, Anti-Tumor Activity And CNS Activity Of Entrectinib In Cancers With TRK, ROS1 Or ALK Fusions Published In Cancer Discovery

  2/9/2017

• Ignyta Release: Late-Breaking Oral Plenary Presentation Of A Novel Entrectinib Combination Regimen At The 2016 EORTC-NCI-AACR Annual Meeting

  12/2/2016

• Ignyta Announces Compelling Phase I/Ib Clinical Data On RXDX-105, Its VEGFR-Sparing RET Inhibitor, At The 2016 EORTC-Ignyta-NCI Annual Meeting

  12/1/2016

• Ignyta To Debut Preclinical Data On RXDX-106 At The 2016 EORTC-NCI-AACR Annual Meeting

  11/29/2016

• Ignyta Announces EAP Designation And CE Marking For Its Trailblaze Pharos Clinical Trial Assay

  11/15/2016

• Ignyta Announces Six Upcoming Presentations At The 2016 EORTC-NCI-AACR Annual Meeting

  11/14/2016

• Ignyta Announces Third Quarter 2016 Company Highlights And Financial Results

  11/8/2016